Analysts expect OncoCyte Corporation (NYSEAMERICAN:OCX) to report $-0.13 EPS on February, 26.They anticipate $0.02 EPS change or 18.18% from last quarter’s $-0.11 EPS. After having $-0.12 EPS previously, OncoCyte Corporation’s analysts see 8.33% EPS growth. The stock decreased 1.47% or $0.05 during the last trading session, reaching $3.35. About 16,402 shares traded. OncoCyte Corporation (NYSEAMERICAN:OCX) has 0.00% since February 10, 2017 and is . It has underperformed by 16.70% the S&P500.
Lpl Financial Llc increased American Wtr Wks Co Inc New (AWK) stake by 15.55% reported in 2017Q3 SEC filing. Lpl Financial Llc acquired 8,311 shares as American Wtr Wks Co Inc New (AWK)’s stock rose 2.78%. The Lpl Financial Llc holds 61,760 shares with $5.00 million value, up from 53,449 last quarter. American Wtr Wks Co Inc New now has $13.90 billion valuation. The stock increased 2.47% or $1.88 during the last trading session, reaching $77.94. About 1.78 million shares traded or 60.40% up from the average. American Water Works Company, Inc. (NYSE:AWK) has risen 3.35% since February 10, 2017 and is uptrending. It has underperformed by 13.35% the S&P500.
Among 12 analysts covering American Water Works (NYSE:AWK), 2 have Buy rating, 0 Sell and 10 Hold. Therefore 17% are positive. American Water Works had 27 analyst reports since October 15, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Ladenburg Thalmann given on Thursday, October 15. The firm has “Neutral” rating by Janney Capital given on Friday, February 26. Northcoast initiated American Water Works Company, Inc. (NYSE:AWK) on Thursday, May 25 with “Neutral” rating. The stock of American Water Works Company, Inc. (NYSE:AWK) earned “Neutral” rating by Bank of America on Wednesday, July 6. The rating was downgraded by HSBC on Wednesday, March 15 to “Hold”. As per Tuesday, December 20, the company rating was upgraded by Janney Capital. The firm earned “Hold” rating on Friday, September 29 by Robert W. Baird. The rating was downgraded by Robert W. Baird on Wednesday, March 2 to “Neutral”. Guggenheim downgraded the stock to “Neutral” rating in Tuesday, January 2 report. Robert W. Baird maintained the shares of AWK in report on Friday, August 25 with “Hold” rating.
Since August 21, 2017, it had 0 buys, and 2 sales for $1.52 million activity. 15,169 American Water Works Company, Inc. (NYSE:AWK) shares with value of $1.24 million were sold by Lynch Walter.
Lpl Financial Llc decreased Shenandoah Telecommunication (NASDAQ:SHEN) stake by 9,400 shares to 8,260 valued at $307,000 in 2017Q3. It also reduced Hollyfrontier Corp (NYSE:HFC) stake by 17,751 shares and now owns 35,845 shares. Bldrs Index Fds Tr (ADRE) was reduced too.
Investors sentiment increased to 1.05 in Q3 2017. Its up 0.05, from 1 in 2017Q2. It improved, as 35 investors sold AWK shares while 185 reduced holdings. 46 funds opened positions while 186 raised stakes. 139.87 million shares or 0.09% less from 140.00 million shares in 2017Q2 were reported. Oppenheimer Asset invested in 0.04% or 19,831 shares. Bluestein R H & stated it has 1.78% in American Water Works Company, Inc. (NYSE:AWK). Tiaa Cref Management Ltd accumulated 0.04% or 683,049 shares. Pictet North America Advsrs invested in 22,835 shares or 0.29% of the stock. Benjamin F Edwards And Communications Inc holds 6,693 shares. The New York-based Silvercrest Asset Management Grp Ltd has invested 0.41% in American Water Works Company, Inc. (NYSE:AWK). Strs Ohio owns 26,649 shares. Hexavest Incorporated reported 4,711 shares. Charter Trust invested 0.04% in American Water Works Company, Inc. (NYSE:AWK). 5,300 were accumulated by De Burlo Group. Btim Corp invested in 28,745 shares or 0.04% of the stock. 10,099 were reported by Creative Planning. Barrett Asset Mgmt Lc accumulated 182 shares. Patten Gp holds 0.11% or 857 shares in its portfolio. Moreover, Employees Retirement System Of Texas has 0.07% invested in American Water Works Company, Inc. (NYSE:AWK).
OncoCyte Corporation focuses on the discovery, development, and commercialization of novel and non-invasive blood and urine diagnostic tests for the early detection of cancer. The company has market cap of $105.28 million. The firm is developing diagnostic tests using proprietary sets of genetic and protein markers expressed in various types of cancer. It currently has negative earnings. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.